388 related articles for article (PubMed ID: 16892696)
1. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
2. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
3. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer.
Delea TE; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Thorac Oncol; 2006 Jul; 1(6):571-6. PubMed ID: 17409919
[TBL] [Abstract][Full Text] [Related]
4. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
5. The cost of treating skeletal-related events in patients with prostate cancer.
Lage MJ; Barber BL; Harrison DJ; Jun S
Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
7. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
9. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
14. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Lung Cancer; 2009 Aug; 65(2):219-22. PubMed ID: 19081161
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
Hagiwara M; Delea TE; Saville MW; Chung K
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
[TBL] [Abstract][Full Text] [Related]
19. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
Hagiwara M; Delea TE; Chung K
J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]